MUMBAI: India's Dr. Reddy's Laboratories Ltd. said on Saturday it has received a US drug regulator approval for the generic version of Geodon capsules, that are used to treat schizophrenia. The Geodon brand, made by Pfizer, had sales of about $1.34 billion in the US in 2011, the Indian drug maker said in a statement.
 

LONDON: An estimated 910,000 lives were saved worldwide over six years thanks to better collaboration between health services to protect people with the AIDS virus from tuberculosis, the World Health Organisation (WHO) said on Friday. The WHO said there had been a sharp rise in the numbers of HIV positive people tested for tuberculosis (TB) and vice versa from 2005 to 2010.
 

NEW YORK: A new review of US data on prostate cancer finds that despite established guidelines, a growing number of men who should not be getting aggressive treatment are getting it anyway. Men with low-risk tumors and a life-expectancy of less than 10 years — for instance, men in their 80s or 90s — are not candidates for so-called curative therapies like radiation or prostate surgery because there's little evidence it would benefit them.
 

NEW YORK: A shortage of beds in hospital intensive care units may mean that more seriously ill patients die, according to a study from France. Researchers focused on 10 hospitals in western France, where there's a known shortage of ICU beds.
 

NEW YORK: Psychotherapy focused on spirituality and finding meaning may help improve quality of life and well-being in terminally ill cancer patients, suggests a new study from a large cancer treatment center. The talk therapy sessions only seemed to provide a short-term benefit — though researchers said that was reasonable given that many of the study participants were near the end of their lives, with progressively worsening disease. The study's lead author said that while hospice and palliative care doctors and nurses are well-versed in treating pain and nausea, for example, there hasn't been definitive evidence on the treatment of non-physical symptoms in very ill patients.
 

NEW YORK (Reuters Health) — A vaccination campaign to prevent teenagers from taking up smoking would be too expensive to recommend, according to Australian researchers who looked at the costs and benefits of anti-nicotine shots in development. Taking into account the effectiveness demonstrated so far by experimental vaccines designed to help smokers quit, the team concluded the drugs would need to be cheaper, require fewer doses and get better results for widespread preventive vaccination of teens to be worthwhile.